US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palvella Therapeutics

25.39

-0.0800-0.31%

Post-market: 25.390.00000.00%16:05 EDT

Volume:65.99K

Turnover:1.66M

Market Cap:279.77M

PE:-3.24

High:26.79

Open:25.06

Low:24.29

Close:25.47

Loading ...

Overview Company News Filings

One Palvella Therapeutics Insider Raised Their Stake In The Previous Year

Simply Wall St.

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Palvella Says US Patent Granted for Qtorin Gel to Treat Rare Skin Disorder

MT Newswires Live

Palvella Therapeutics granted U.S patent for QTORIN Rapamycin

Palvella Therapeutics Granted Additional U.S. Patent for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

THOMSON REUTERS

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics announces data on QTORIN rapamycin

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Director Makes Bold Move with Major Stock Purchase in Palvella Therapeutics!

Palvella Therapeutics Initiated at Buy by Chardan Capital

Chardan Initiates Palvella Therapeutics at Buy With $50 Price Target

MT Newswires Live

Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.

Palvella Therapeutics (PVLA) Receives a Buy from Scotiabank

Palvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Palvella Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

CORRECTION: Palvella Therapeutics FY24 GAAP EPS $(7.83) Misses $2.10 Estimate, Cash Balance Of $83.6M Expected To Fund Operations Into The Second Half Of 2027

Palvella Therapeutics Q4 EPS $(7.83) Misses $(3.02) Estimate

Palvella Therapeutics reports FY24 EPS ($7.83), consensus ($3.01)

Press Release: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PVLA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":25.39,"timestamp":1745611200000,"preClose":25.47,"halted":0,"volume":65991,"hourTrading":{"tag":"盘后","latestPrice":25.39,"preClose":25.39,"latestTime":"16:05 EDT","volume":119,"amount":3021.41,"timestamp":1745611513608},"delay":0,"floatShares":6292255,"shares":11018747,"eps":-7.832217,"marketStatus":"Market Closed","change":-0.08,"latestTime":"04-25 16:00:00 EDT","open":25.06,"high":26.79,"low":24.29,"amount":1656488.118,"amplitude":0.098155,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.832217,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":25.47,"preHourTrading":{"tag":"盘前","latestPrice":25.89,"preClose":25.47,"latestTime":"04:05 EDT","volume":2,"amount":49.239998,"timestamp":1745568323112},"postHourTrading":{"tag":"盘后","latestPrice":25.39,"preClose":25.39,"latestTime":"16:05 EDT","volume":119,"amount":3021.41,"timestamp":1745611513608},"volumeRatio":0.5812802236780464,"impliedVol":0.261,"impliedVolPercentile":0.3934},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":6292255,"roa":"-18.39%","roe":"-59.37%","lyrEps":-7.832217,"volumeRatio":0.5812802236780464,"shares":11018747,"dividePrice":0,"high":26.79,"amplitude":0.098155,"preClose":25.47,"low":24.29,"week52Low":6.2,"pbRate":"4.47","week52High":29.27,"institutionHeld":0,"latestPrice":25.39,"eps":-7.832217,"divideRate":0,"volume":65991,"delay":0,"ttmEps":-7.832217,"open":25.06,"prevYearClose":12,"prevWeekClose":24.36,"prevMonthClose":27.99,"prevQuarterClose":27.99,"fiveDayClose":24.36,"twentyDayClose":27.76,"sixtyDayClose":13.31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530226961","title":"One Palvella Therapeutics Insider Raised Their Stake In The Previous Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2530226961","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530226961?lang=en_us&edition=fundamental","pubTime":"2025-04-26 22:28","pubTimestamp":1745677685,"startTime":"0","endTime":"0","summary":"Insiders were net buyers of Palvella Therapeutics, Inc.'s  stock during the past year. That is, insiders bought more stock than they sold.Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.Palvella Therapeutics Insider Transactions Over The Last Year. In the last twelve months, the biggest single purchase by an insider was when Independent Chairman of the Board George Jenkins bought US$52k worth of shares at a price of US$12.93 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$25.39. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's pric","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/one-palvella-therapeutics-insider-raised-142805102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2529101668","title":"Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2529101668","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529101668?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:15","pubTimestamp":1745439300,"startTime":"0","endTime":"0","summary":"Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations  with cutaneous involvement. Estimates of annual incidence of LMs with cutaneous involvement to be highlighted in the poster presentation. WAYNE, Pa., April 23, 2025  --  Palvella Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration -approved therapies, today announced an abstract highlighting the estimated diagnosed prevalence and annual incidence of lymphatic malformation  cases in the U.S. was accepted for poster presentation at the Society for Investigative Dermatology  Annual Meeting, taking placeMay 7-10, 2025, inSan Diego, California.“This study is the first to quantify the U.S. LM population based on a rigorous, quantitative analysis of medical claims data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-announces-abstract-highlighting-201500649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SID","BK4006","PVLA"],"gpt_icon":0},{"id":"2529587195","title":"Palvella Says US Patent Granted for Qtorin Gel to Treat Rare Skin Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2529587195","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529587195?lang=en_us&edition=fundamental","pubTime":"2025-04-22 22:23","pubTimestamp":1745331790,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) said Tuesday the US Patent and Trademark Office has granted a fifth patent for its product candidate Qtorin 3.9% rapamycin anhydrous gel in treating microcystic lymphatic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2529370130","title":"Palvella Therapeutics granted U.S patent for QTORIN Rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2529370130","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529370130?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:37","pubTimestamp":1745321876,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced that the United States Patent and Trademark Office, USPTO, issued patent No. 12,268,673 for claims related t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-granted-u-s-patent-for-qtorin-rapamycin?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-granted-u-s-patent-for-qtorin-rapamycin?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2529779103","title":"Palvella Therapeutics Granted Additional U.S. Patent for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2529779103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529779103?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:30","pubTimestamp":1745321400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUACBHYHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2529020370","title":"Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2529020370","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529020370?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:30","pubTimestamp":1745321400,"startTime":"0","endTime":"0","summary":"Fifth issued patent in the U.S. for QTORIN rapamycin with anticipated patent life extending into 2038. QTORIN rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S.The granted patent “Anhydrous Compositions of mTOR Inhibitors and Methods of Use” broadens protection for QTORIN rapamycin and the conditions related to its use in clinical indications, including microcystic LMs.QTORIN rapamycin has been granted Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the U.S. FDA for the treatment of microcystic LMs. In addition to granted patents, it is anticipated that QTORIN rapamycin will be eligible for seven years of orphan drug market exclusivity in theU.S., if approved.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-granted-additional-u-113000173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2526650002","title":"Palvella Therapeutics announces data on QTORIN rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2526650002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526650002?lang=en_us&edition=fundamental","pubTime":"2025-04-11 19:36","pubTimestamp":1744371416,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced QTORIN rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations was featured by...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-announces-data-on-qtorin-rapamycin?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-announces-data-on-qtorin-rapamycin?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2526265029","title":"Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2526265029","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526265029?lang=en_us&edition=fundamental","pubTime":"2025-04-11 19:30","pubTimestamp":1744371000,"startTime":"0","endTime":"0","summary":"Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old Presentation reviewed clinically and statistically significant Phase 2 results and the des","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/11/3060025/0/en/Palvella-Therapeutics-Announces-QTORIN-Rapamycin-3-9-Anhydrous-Gel-for-the-Treatment-of-Microcystic-Lymphatic-Malformations-Featured-in-Oral-Presentation-by-Amy-Paller-M-S-M-D-Chai.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IEC","BK4208","WDS","SPD","BK4006","PVLA","NWE","SID","BK4213","BK4139"],"gpt_icon":0},{"id":"2526571183","title":"Director Makes Bold Move with Major Stock Purchase in Palvella Therapeutics!","url":"https://stock-news.laohu8.com/highlight/detail?id=2526571183","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526571183?lang=en_us&edition=fundamental","pubTime":"2025-04-11 10:02","pubTimestamp":1744336944,"startTime":"0","endTime":"0","summary":"New insider activity at Palvella Therapeutics ( ($PVLA) ) has taken place on April 11, 2025. Director George M. Jenkins has made a significant inve...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-palvella-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-stock-purchase-in-palvella-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA","BK4141","MMAT"],"gpt_icon":0},{"id":"2526352497","title":"Palvella Therapeutics Initiated at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2526352497","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526352497?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:12","pubTimestamp":1744197120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 07:12 ET (11:12 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2526735941","title":"Chardan Initiates Palvella Therapeutics at Buy With $50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2526735941","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526735941?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:35","pubTimestamp":1744194959,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) has an average rating of buy and mean price target of $49.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"gpt_icon":0},{"id":"2524205040","title":"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524205040","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524205040?lang=en_us&edition=fundamental","pubTime":"2025-04-04 20:00","pubTimestamp":1743768000,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., April 04, 2025  --  Palvella Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration -approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer ofPalvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT.QTORIN rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-present-jones-healthcare-120000124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4137","HCSG","PVLA"],"gpt_icon":0},{"id":"2524118947","title":"Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524118947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524118947?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:05","pubTimestamp":1743509100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 08:05 ET (12:05 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2524194968","title":"Palvella Therapeutics (PVLA) Receives a Buy from Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2524194968","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524194968?lang=en_us&edition=fundamental","pubTime":"2025-04-01 18:56","pubTimestamp":1743504973,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen maintained a Buy rating on Palvella Therapeutics (PVLA – Research Report) today and set a price target of $50.00. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2524745163","title":"Palvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2524745163","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524745163?lang=en_us&edition=fundamental","pubTime":"2025-04-01 15:01","pubTimestamp":1743490904,"startTime":"0","endTime":"0","summary":"Cash and Cash Equivalents: $83.6 million as of December 31, 2024.Cash Runway: Expected to extend into the second half of 2027.Research and Development Expenses: $8.2 million for the full-year 2024, compared to $8.8 million in 2023.General and Administrative Expenses: $5.9 million for the full-year 2024, compared to $3.1 million in 2023.Net Loss: $17.4 million or $7.83 per diluted share for the full-year 2024.Net Income : $17.9 million or $2.17 per diluted share for 2023.Projected Cash Spend for 2025: Approximately $30 million.Projected R&D Spend for 2025: $18 million to $20 million.Projected G&A Spend for 2025: $10 million to $12 million.Expected Year-End 2025 Cash Balance: At least $55 million.GuruFocus has detected 3 Warning Signs with ITXXF.Palvella Therapeutics Inc  is leveraging the 505 regulatory pathway for its NDA submission, which could streamline the drug review process and expedite approval.Palvella Therapeutics Inc  reported a net loss of $17.4 million for the full-year 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-inc-pvla-q4-070144507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PVLA"],"gpt_icon":0},{"id":"2523422299","title":"Palvella Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2523422299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523422299?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:31","pubTimestamp":1743427908,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryPalvella Therapeutics Inc PVLA.OQ reported a quarterly adjusted loss of $2.72 per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL5N3QE0ZE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2523908945","title":"CORRECTION: Palvella Therapeutics FY24 GAAP EPS $(7.83) Misses $2.10 Estimate, Cash Balance Of $83.6M Expected To Fund Operations Into The Second Half Of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2523908945","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523908945?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:07","pubTimestamp":1743422863,"startTime":"0","endTime":"0","summary":"CORRECTION: Palvella Therapeutics FY24 GAAP EPS $(7.83) Misses $2.10 Estimate, Cash Balance Of $83.6M Expected To Fund Operations Into The Second Half Of 2027","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44559811/correction-palvella-therapeutics-fy24-gaap-eps-7-83-misses-2-10-estimate-cash-balance-of-83-6m-expe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2523198948","title":"Palvella Therapeutics Q4 EPS $(7.83) Misses $(3.02) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523198948","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523198948?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:36","pubTimestamp":1743421019,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(7.83) per share which missed the analyst consensus estimate of $(3.02) by 159.27 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44558839/palvella-therapeutics-q4-eps-7-83-misses-3-02-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2523943353","title":"Palvella Therapeutics reports FY24 EPS ($7.83), consensus ($3.01)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523943353","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523943353?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:36","pubTimestamp":1743421017,"startTime":"0","endTime":"0","summary":"“2024 was marked by significant progress towards achieving our vision of becoming the leading rare disease biopharmaceutical company focused on ser...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-reports-fy24-eps-7-83-consensus-3-01?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-reports-fy24-eps-7-83-consensus-3-01?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2523194839","title":"Press Release: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523194839","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523194839?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:30","pubTimestamp":1743420600,"startTime":"0","endTime":"0","summary":"Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases. Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN 3.9% rapamycin anhydrous gel  for the treatment of microcystic lymphatic malformations , on track for the first quarter of 2026. Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN rapamycin for the treatment of cutaneous venous malformations , on track for the fourth quarter of 2025. Planned QTORIN pipeline expansion in second half of 2025. Cash and cash equivalents of over $83 million as of December 31, 2024 expected to fund operations into the second half of 2027. Mr. Kaupinen continued, \"In addition to these two initial indications for QTO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4585","LU0566484027.USD","TM","BK4139","BK4604","BK4555","LU1559883803.SGD","03160","BK4007","BK4099","BK4588","LGND"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19},{"market":"US","date":"2024-08-14","symbol":"PVLA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-2.76},{"market":"US","date":"2024-05-15","symbol":"PVLA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-3.95},{"market":"US","date":"2024-04-23","symbol":"PVLA","defaultRemindTime":1713879000000,"type":"split","dateTimestamp":1713844800000,"forFactor":80,"toFactor":1,"ratio":80}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.8889,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8889,"analysts":9,"updateTime":1744257600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2025-04-25","current":-16.097711,"percent":0.037975,"low":-17.359106,"twenty":-12.583644,"median":23.043756,"eighty":39.236406,"high":46.119317,"avg":20.495462,"sd":20.299797,"marketCap":280647486},"quantilePoints":[{"date":"2025-01-03","current":19.083855,"twenty":19.083855,"median":19.083855,"eighty":19.083855,"marketCap":134655684},{"date":"2025-01-10","current":22.662078,"twenty":19.083855,"median":20.077806,"eighty":23.120091,"marketCap":159903624},{"date":"2025-01-17","current":21.024047,"twenty":19.083855,"median":21.024047,"eighty":22.483962,"marketCap":148345678},{"date":"2025-01-24","current":20.658273,"twenty":19.395558,"median":20.960435,"eighty":22.003685,"marketCap":145764777},{"date":"2025-01-31","current":21.469337,"twenty":19.914003,"median":20.93658,"eighty":21.408905,"marketCap":151487644},{"date":"2025-02-07","current":23.854819,"twenty":20.19708,"median":20.960435,"eighty":22.191343,"marketCap":168319605},{"date":"2025-02-14","current":31.806426,"twenty":20.537409,"median":21.047902,"eighty":23.471552,"marketCap":224426140},{"date":"2025-02-21","current":30.216104,"twenty":20.626467,"median":21.159225,"eighty":24.999851,"marketCap":213204833},{"date":"2025-02-28","current":29.977556,"twenty":20.64237,"median":22.089563,"eighty":29.977556,"marketCap":211521636},{"date":"2025-03-07","current":38.072292,"twenty":20.658273,"median":23.043756,"eighty":30.804523,"marketCap":268638089},{"date":"2025-03-14","current":43.224933,"twenty":20.674177,"median":23.473142,"eighty":31.806426,"marketCap":304995124},{"date":"2025-03-21","current":43.622513,"twenty":20.674177,"median":24.864674,"eighty":35.527777,"marketCap":307800451},{"date":"2025-03-28","current":44.147319,"twenty":20.912725,"median":26.844623,"eighty":43.224933,"marketCap":311503482},{"date":"2025-04-04","current":-15.431096,"twenty":20.674177,"median":26.264156,"eighty":43.368061,"marketCap":269025725},{"date":"2025-04-11","current":-12.558363,"twenty":20.515145,"median":24.729496,"eighty":43.224933,"marketCap":218942502},{"date":"2025-04-17","current":-15.421442,"twenty":19.083855,"median":23.473142,"eighty":40.654974,"marketCap":268857426},{"date":"2025-04-25","current":-16.097711,"twenty":-12.583644,"median":23.043756,"eighty":39.236406,"marketCap":280647486}],"updateTime":1745740142364}}}